The current BUY / SELL / HOLD call for Novartis at each published horizon (one, three and six months), produced by a 10-model statistical ensemble combined with pattern recognition and market sentiment. Every call below was recorded before its outcome was known and is scored publicly.
No published call for NOVN.SW yet. Run a live NOVN.SW forecast →
A call is a hit when the market moves the way it was called. HOLD is not scored — it is a decision not to call. The benchmark is not 50%: equities drift upward, so the honest bar is what "always buy" would have scored over the same window — roughly 53% at one month, 58% at three, 62% at six.
Informational only. finXPN is not a financial advisor and this is not investment advice. Forecasts are statistical estimates, not guarantees.
No call for Novartis has been published yet. Calls appear here once one has been recorded.
No Novartis call has reached its target date yet. Nothing is scored before the date arrives, so there is no accuracy figure to show for this instrument yet.
Thirteen statistical forecasting models are run on Novartis's price history and combined into one ensemble. Candlestick pattern recognition, technical indicators and news sentiment are fused with that ensemble into a single BUY, SELL or HOLD call per horizon, with a confidence figure. Weak evidence returns HOLD rather than a guess.
No. finXPN publishes statistical forecasts for information and research only. It is not a financial adviser, the calls are not investment advice or a recommendation to trade Novartis, and past accuracy does not guarantee future results.
70 instruments across 13 markets carry a published daily call. Browse the full list.